Lakhani et al. analysed FGF21 in different cardiometabolic disorders, including metabolic syndrome, diabetes, diabetic nephropathy, CAD, and cardiovascular motality, and reported elevated FGF21 levels were significant predictors of these disorders [105]. This evidence concerns the gene FGF21 and coronary artery disorder.